Ann: 84 German hospitals can negotiate fee for Oncosil device, page-4

Tiny, great news this is

The authorization for 84 German hospitals to negotiate funding for the OncoSilTM device under the innovation funding (NUB) program represents a significant milestone for OncoSil Medical Ltd.

This development is a testament to the growing recognition and demand for innovative treatments for locally advanced pancreatic cancer (LAPC) in Germany. Here are some key implications of this development for OncoSil Medical:

Increased Accessibility and Demand: The authorization facilitates increased accessibility of the OncoSilTM device to patients in need within Germany. As demand grows, as evidenced by the tripling of hospitals submitting requests for NUB funding since 2021, it underscores the medical community's recognition of the device's potential benefits.

Revenue Growth Opportunities: With more hospitals able to negotiate funding, there's a clear path for increased adoption and use of the OncoSilTM device. This can lead to significant revenue growth for OncoSil Medical as the device becomes more integrated into standard treatment protocols for LAPC in Germany.

Market Penetration: Successfully entering the German market, one of Europe's largest healthcare markets, can significantly enhance OncoSil's market penetration. This could lead to further opportunities within Europe, enhancing the company's growth prospects and profitability.

Stable Revenue Stream: The NUB program's support provides a mechanism for hospitals to adopt new and innovative treatments like the OncoSilTM device, potentially leading to a more stable and predictable revenue stream from the German market.

Very significant good news for patients and our company.
-----

The new distribution agreement between OncoSil Medical Ltd and EDH Nuclear Medicine & Healthcare Services for the Turkish market has several implications for OncoSil's profitability:

Market Expansion: By entering the Turkish market, OncoSil opens up to a significant new patient base. With a population of 85 million, Turkey represents a large and growing addressable market for OncoSil's device. Expanding into this market could lead to increased sales volumes, contributing positively to the company's revenue.

Strategic Partnership: EDH's strong presence and established reputation in nuclear medicine and healthcare services, not just in Turkey but also in Central and Eastern Europe, North Africa, the Middle East, Gulf Countries, and other Turkic Republics, provide OncoSil with a strategic advantage. This partnership can facilitate smoother market entry, potentially leading to quicker adoption and higher sales of the OncoSilTM device.

Increased Visibility and Adoption: The collaboration aims to leverage EDH's network and expertise to increase the visibility and adoption of the OncoSilTM device. Rapid adoption, as anticipated by both parties, could lead to a significant increase in demand, directly impacting OncoSil's profitability positively.

....